Core Insights - Crinetics Pharmaceuticals' stock surged 27.9% after the FDA approved its acromegaly drug, Palsonify, which is expected to become the standard of care for an under-treated population [1][3][4] Pricing and Market Expectations - Palsonify is priced at $290,000 per year, significantly higher than the expected $80,000, indicating a strong market positioning [2] - Analysts expect a gradual launch as patients navigate the healthcare system to consult with physicians [3][5] Competitive Landscape - Existing treatments for acromegaly include injectable hormones from companies like Novartis and Ipsen, but analysts predict these legacy drugmakers may reduce support for older drugs, allowing Crinetics to gain market share [4] - Crinetics has deployed approximately 80 commercial personnel, including experienced sales representatives, to support the launch [5] Launch Strategy - The company plans to begin taking orders immediately, with shipments expected to start in October, although the initial launch may be slow due to the need for formulary placements [5] - Analysts maintain an outperform rating on Crinetics stock, with a price target of $80 [4][6]